Xenon Pharmaceuticals Inc

Day range

$35.09 – $35.72

Open

$35.34

Prev close

$35.34

Volume

300.17K

Market cap

$3.42B

Shares out

96.67M

P/E

—

P/S

—

P/B

2.75

P/FCF

—

ROE

-32.9%

ROA

-31.6%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Annual meeting resultsJun 3, 2026

  At the Annual Meeting, 90,399,636.29 of the Company's common shares, or approximately 93.54% of the total common shares entitled to vote, were present or represented by proxies and voted on the following proposals... The following nominees were elected as directors to serve until the 2027 annual meeting of shareholders or until their respective successors are duly elected and qualified: Dawn Svoronos, Gillian Cannon, Steven Gannon, Elizabeth Garofalo, Justin Gover, Patrick Machado, Ian Mortimer, Gary Patou.

• Equity compensation grantApr 13, 2026

  amended and restated the Company's Amended and Restated 2025 Inducement Equity Incentive Plan to increase the maximum number of shares of its common stock reserved for issuance under the 2025 Inducement Plan from 900,000 shares to 1,175,000 shares to be used exclusively for grants of nonstatutory stock options, stock appreciation rights, restricted stock units, restricted stock, and performance awards as an inducement material to individuals being hired, or rehired following a bona fide period of interruption of employment

• Shareholder meeting noticeMar 13, 2026

  On March 13, 2026, Xenon Pharmaceuticals Inc. announced the meeting, record date and certain other information relating to its 2026 annual meeting of shareholders pursuant to a filing submitted to the System for Electronic Document Analysis and Retrieval in Canada.

• Public offeringMar 12, 2026

  On March 10, 2026, Xenon Pharmaceuticals Inc. (the "Company") entered into an underwriting agreement relating to an underwritten public offering of 12,236,843 common shares (the "Firm Shares") and pre-funded warrants to purchase 877,194 common shares at an exercise price equal to $0.0001 per share (the "Pre-Funded Warrants") being sold by the Company. The offering price of the Firm Shares to the public is $57.00 per common share, and the offering price of the Pre-Funded Warrants to the public is $56.9999 per Pre-Funded Warrant.

• Clinical trial resultsMar 9, 2026

  On March 9, 2026, Xenon Pharmaceuticals Inc. (the "Company") issued a press release announcing topline data from the Company's Phase 3 X-TOLE2 study of azetukalner in focal onset seizures

Days to cover

1.6

Short interest

6.04M

Avg volume

3.83M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
  negativeGlobeNewswire Inc.· Oct 20, 2026
• XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?
  negativeZacks Investment Research· Oct 15, 2026
• XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback
  Zacks Investment Research· Sep 18, 2026
• Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight
  positiveGlobeNewswire Inc.· Jun 10, 2026
• Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
  positiveGlobeNewswire Inc.· Apr 19, 2026